Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by houbahopon Dec 07, 2022 4:52am
224 Views
Post# 35155513

RE:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On

RE:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims OnWho bought 7.5m shares of THTX on November 14th?

The way Theratechnologies has been behaving with its shareholders for the last 15 years merits a class action.

On the other side, all the members of Thera Fan Club using this forum are very much aware the Board of Directors has been mismanaging its fiduciary duties during all this period. The high turnover of people sitting in the Investor Relation unconfortable chair reflects the racket behind the curtains.

So all of you, Thera Fan Club, don't complain if this company drives its shares under a buck. You have chosen to be blind to the simple facts.

This forum is becoming messy.
<< Previous
Bullboard Posts
Next >>